Freezing eggs to get ahead: a look at oocyte cryopreservation for non-medical reasons

Contenu principal de l'article

Jenny Han Zhang

Résumé

The age of first pregnancies for women has been on the rise, partly due to prioritization of career development. Maternal aging is a significant factor affecting fertility, and is correlated with infertility and several adverse pregnancy outcomes. Oocyte cryopreservation (OC), currently recommended to cancer patients pending treatments affecting fertility, is now being explored as an option for extending female fertility due to its efficacy in in vitro fertilization (IVF). However, there is a paucity of data confirming the superiority of the procedure over natural pregnancy in healthy women, given the potential complications. Caution in recommending the procedure should therefore be taken. 

Résumé

L’âge des premières grossesses chez les femmes a augmenté, en partie à cause de la hiérarchisation du développement de carrière. Le vieillissement maternel est un facteur important affectant la fertilité, et est corrélé avec l’infertilité et plusieurs résultats défavorables de la grossesse. La cryoconservation des ovocytes (CO), recommandée aux patients cancéreux en attendant les traitements affectant la fertilité, est actuellement explorée comme une option pour augmenter la fertilité féminine en raison de son efficacité dans la fécondation in vitro (FIV). Cependant, il y a un manque de données confirmant la supériorité de la procédure sur la grossesse naturelle chez les femmes en bonne santé, étant donné les complications potentielles. La prudence dans la recommandation de la procédure devrait donc être prise. 

Renseignements sur l'article

Rubrique
Commentary

Références

1. Statistics Canada - Government of Canada. Trends in Canadian births, 1993 to 2013 [Internet]. Statistics Canada. 2016 Oct 26 [cited 2017 Sept 27] . Available from: http://www.statcan.gc.ca/pub/82-625-x/2016001/ article/14673-eng.htm#a2.

2. Liu K, Case A. Advanced reproductive age and fertility. J Obstet Gynaecol Canada. 2011;33(11):1165-75.

3. Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med. 1982;306(7):404-6.

4. Spandorfer S, Davis O, Barmat L, Pak C, Rosenwaks Z. Relationship between maternal age and aneuploidy in in vitro fertilization pregnancy loss. Fertil Steril. 2003;81(5):1265-9.

5. Cleary-Goldman J, Malone F, Vidaver J, et al. Impact of maternal age on obstetric outcome. Obstet Gynecol. 2005;105(5):983-90.

6. Hassold T, Hunt P. Maternal age and chromosomally abnormal pregnancies: what we know and what we wish we knew. Curr Opin Pediatr. 2009;21(6):703-8.

7. Duncan FE. Egg quality during the pubertal transition—is youth all it’s cracked up to be? Front Endocrinol (Lausanne). 2017;8:1-5.

8. Government of Ontario. Get fertility treatments [Internet]. Government of Ontario. 2017 May 9 [cited 2017 Sept 27]. Available from: https://www.ontario.ca/page/get-fertility-treatments.

9. The Montreal Fertility Centre. Quebec Program of Assisted Reproduction [Internet]. The Montreal Fertility Centre. 2017 [cited 2017 Sept 27]. Available from: http://www.montrealfertility.com/quebec-program-of-assisted-reproduction/.

10. Dhillon RK, McLernon DJ, Smith PP, et al. Predicting the chance of live birth for women undergoing IVF: a novel pretreatment counselling tool. Hum Reprod. 2016;31(1):84-92.

11. Chian R-C, Xu Y, Keilty D. Cryopreservation of mammalian gametes and em- bryos. New York, NY: Humana Press; 2017. Chapter 3, Current challenges in immature oocyte cryopreservation; p. 33–44.

12. Cobo A, Kuwayama M, Pérez S, Ruiz A, Pellicer A, Remohí J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. Fertil Steril. 2007;89(6):1657-64.

13. Danasouri IE, Selman H. Vitrification versus conventional cryopreservation technique. Middle East Fertil Soc J. 2005;10(3):205-6.

14. Massarotti C, Scaruffi P, Lambertini M, Remorgida V, Del Mastro L, Anserini P. State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. Cancer Treat Rev. 2017;57:50-7.

15. Noyes N, Labella PA, Grifo J, Knopman JM. Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. J Assist Reprod Genet. 2010;27(8):495-9.

16. Hammarberg K, Kirkman M, Pritchard N, et al. Reproductive experiences of women who cryopreserved oocytes for non-medical reasons. Hum Reprod. 2017;32(3):575-81.

17. Flinders Fertility. Information statement - ovulation induction risks [Internet]. Flinders Fertility. 2016 [cited 2017 Sep 30]. Available from: http://www. flindersfertility.com.au/Research-Resources/Information-Statements/Ovulation-Induction-Risks.

18. Kumar P, Sait SF, Sharma A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4(2):70-5.

19. Onalen G, Zeyneloglu HB. Manual of ovulation induction and ovarian stimulation protocols. In: Allahbadia G, Merchant R, eds. Ovarian Stimulation Procedures. 3rd ed. JP Medical Ltd.; 2016. 649 p.

20. Rose BI. Approaches to oocyte retrieval for advanced reproductive technology cycles planning to utilize in vitro maturation: a review of the many choices to be made. J Assist Reprod Genet. 2014;31(11):1409-19.

21. Choudhary RA, Bhise NM, Mehendale A V, Ganla KN. Ureteric injury during transvaginal oocyte retrieval (TVOR) and review of literature. J Hum Reprod Sci. 2017;10(1):61-4.

22. Zore T, Joshi N, Schon SB, Masson P, Chan JL. Assessment of fertility clinic websites on oocyte cryopreservation (OC). Fertil Steril. 2017;108(3):e189.